Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jan-Feb;77(1):42-44.
doi: 10.1016/j.ihj.2025.01.002. Epub 2025 Jan 12.

Efficacy of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in right ventricular systolic dysfunction and preserved LV ejection fraction: A randomized clinical trial

Rohit Mathur  1 , Anil Baroopal  2 , Chaina Ram Chaudhary  3 , Afjal Hakim  4 , Manoj Verma  4
Affiliations
Randomized Controlled Trial

Efficacy of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in right ventricular systolic dysfunction and preserved LV ejection fraction: A randomized clinical trial

Rohit Mathur et al. Indian Heart J. 2025 Jan-Feb.

Abstract

Angiotensin Receptor Neprilysin Inhibitor (ARNI) has not shown to be promising in Heart failure with preserved LVEF. Role of ARNI in Right ventricular systolic dysfunction with preserved LVEF needs to be evaluated. We took 50 patients with isolated RV systolic dysfunction and divided them into two groups of 25 patients each- Conventional treatment and ARNI in addition to conventional treatment. We found that the ARNI group showed a significant improvement in NYHA class, all the echo parameters of RV size, RV function and NT-pro BNP levels at 4 weeks and 12 weeks.

Keywords: Angiotensin Receptor Neprilysin Inhibitor; Heart failure; NT-pro BNP; Right ventricular systolic dysfunction.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Dose of ARNI at different follow up time.
See this image and copyright information in PMC

References

    1. Benjamin E.J., Virani S.S., Callaway C.W., et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492. - PubMed
    1. Sato N. Epidemiology of heart failure in Asia. Heart Fail Clin. 2015;11:573–579. - PubMed
    1. Padang R., Chandrashekar N., Indrabhinduwat M., et al. Aetiology and outcomes of severe right ventricular dysfunction. Eur Heart J. 2020;41:1273–1282. - PubMed
    1. Panagopoulou V., Deftereos S., Kossyvakis C., et al. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013;13(2):82–94. doi: 10.2174/1568026611313020002. PMID: 23470072. - DOI - PubMed
    1. De Simone V., Guarise P., Zanotto G., et al. Reduction in pulmonary artery pressures with use of sacubitril/valsartan. J Cardiol Cases. 2019 Nov 1;20(5):187–190. - PMC - PubMed

Publication types

MeSH terms